$MDBH
MDB Capital Holdings LLC Stock $mdbh

$mdbh Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041312 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q1
Revenue	$974.1K	-$775.4K	$117.0K
YoY Change	-12.67%	-1207.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.041M	$2.496M	$2.241M
YoY Change	258.7%	13.44%
% of Gross Profit
Research & Development	$461.1K	$27.94K	$31.59K
YoY Change	781.44%	-73.04%
% of Gross Profit
Depreciation & Amortization	$58.97K	$49.72K	$44.12K
YoY Change	36.69%	24.3%
% of Gross Profit
Operating Expenses	$7.502M	$2.524M	$2.272M
YoY Change	272.27%	9.62%
Operating Profit		-$775.4K	$117.0K
YoY Change		-1148.2%
Interest Expense	$370.9K	$176.3K	$187.3K
YoY Change	63.2%
% of Operating Profit			160.09%
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.207M	-$3.123M	-$1.968M
YoY Change	822.98%	40.14%
Income Tax	-$256.2K	$63.56K	$0.00
% Of Pretax Income
Net Earnings	-$5.549M	-$3.186M	-$1.968M
YoY Change	946.77%	42.99%	82.44%
Net Earnings / Revenue	-569.72%		-1682.14%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.60	-$0.32	-$0.20
COMMON SHARES
Basic Shares Outstanding	4.296M shares	2.629M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.358M	$24.45M	$3.471M
YoY Change	48.56%	110.92%
Cash & Equivalents	$6.110M	$24.45M	$3.471M
Short-Term Investments
Other Short-Term Assets	$523.8K	$561.5K	$205.3K
YoY Change	69.06%	274.36%
Inventory
Prepaid Expenses
Receivables	$882.3K	$676.5K	$1.013M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.764M	$25.68M	$4.689M
YoY Change	44.33%	104.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$866.5K	$842.3K	$1.940M
YoY Change	38.72%	-33.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$30.89M	$12.81M	$16.82M
YoY Change	78.85%	12.77%
Other Assets	$144.6K	$2.000M	$595.6K
YoY Change	-55.25%	316.67%
Total Long-Term Assets	$3.187M	$17.78M	$19.35M
YoY Change	56.64%	35.51%
TOTAL ASSETS
Total Short-Term Assets	$8.764M	$25.68M	$4.689M
Total Long-Term Assets	$3.187M	$17.78M	$19.35M
Total Assets	$42.99M	$43.46M	$24.04M
YoY Change	67.25%	69.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$578.2K	$1.040M	$1.115M
YoY Change	-17.25%	70.51%
Accrued Expenses	$3.521M	$2.364M	$1.553M
YoY Change	109.8%	105.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.524M	$3.763M	$2.668M
YoY Change	132.41%	113.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$140.7K	$153.7K	$179.6K
YoY Change	-34.56%	-26.83%
Total Long-Term Liabilities	$140.7K	$153.7K	$179.6K
YoY Change	-34.56%	-26.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.524M	$3.763M	$2.668M
Total Long-Term Liabilities	$140.7K	$153.7K	$179.6K
Total Liabilities	$5.665M	$4.142M	$3.276M
YoY Change	118.56%	55.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.09M	-$6.255M
YoY Change	136.0%
Common Stock		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.31M	$39.02M	$20.77M
YoY Change
Total Liabilities & Shareholders Equity	$42.99M	$43.46M	$24.04M
YoY Change	67.25%	69.12%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q1
OPERATING ACTIVITIES
Net Income	-$5.549M	-$3.186M	-$1.968M
YoY Change	946.77%	42.99%	82.44%
Depreciation, Depletion And Amortization	$58.97K	$49.72K	$44.12K
YoY Change	36.69%	24.3%
Cash From Operating Activities	-$2.052M	-$1.388M	-$1.203M
YoY Change	25.34%	-45.13%
INVESTING ACTIVITIES
Capital Expenditures	$83.15K	$311.9K	$6.940K
YoY Change	169.7%	939.8%
Acquisitions
YoY Change
Other Investing Activities	-$16.88M	$7.516M
YoY Change	229.26%	-167.96%
Cash From Investing Activities	-$16.97M	$7.204M	-$6.940K
YoY Change	228.9%	-164.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-69.30K	18.24M	-272.3K
YoY Change	-144.04%	-680.84%
NET CHANGE
Cash From Operating Activities	-2.052M	-1.388M	-1.203M
Cash From Investing Activities	-16.97M	7.204M	-6.940K
Cash From Financing Activities	-69.30K	18.24M	-272.3K
Net Change In Cash	-19.09M	24.05M	-1.482M
YoY Change	187.55%	-243.52%
FREE CASH FLOW
Cash From Operating Activities	-$2.052M	-$1.388M	-$1.203M
Capital Expenditures	$83.15K	$311.9K	$6.940K
Free Cash Flow	-$2.135M	-$1.700M	-$1.210M
YoY Change	28.01%	-33.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001934642
CY2022Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent		usd
CY2022Q4	MDBH	Deferred Tax Liabilities Net Current DeferredTaxLiabilitiesNetCurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023Q3	us-gaap	Fee Income FeeIncome		usd
CY2022Q3	us-gaap	Fee Income FeeIncome		usd
	us-gaap	Fee Income FeeIncome		usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	MDBH	Adjustments To Additional Paid In Capital Ownership Change Of Noncontrolling Interest AdjustmentsToAdditionalPaidInCapitalOwnershipChangeOfNoncontrollingInterest		usd
CY2022Q3	MDBH	Adjustments To Additional Paid In Capital Ownership Change Of Noncontrolling Interest AdjustmentsToAdditionalPaidInCapitalOwnershipChangeOfNoncontrollingInterest		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	MDBH	Accretion Of Investments At Amortized Cost Us Treasury Bills AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills		usd
	MDBH	Payments To Acquire Investment Securities At Fair Value Made By Our Licensed Broker Dealer PaymentsToAcquireInvestmentSecuritiesAtFairValueMadeByOurLicensedBrokerDealer		usd
	MDBH	Payments For Proceeds Purchases Of Investment Securities At Cost Less Impairment PaymentsForProceedsPurchasesOfInvestmentSecuritiesAtCostLessImpairment		usd
	MDBH	Proceeds From Sale Of Investment Securities At Fair Value ProceedsFromSaleOfInvestmentSecuritiesAtFairValue		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	MDBH	Proceeds From Warrants Issued As Part Of Investment Banking Deal ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal		usd
	MDBH	Income Recognized From Warrants Received IncomeRecognizedFromWarrantsReceived		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable		usd
	MDBH	Proceeds Of Investments Securities At Amortized Cost Us Treasury Bills ProceedsOfInvestmentsSecuritiesAtAmortizedCostUSTreasuryBills		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	MDBH	Payment Of Deferred Costs Of Initial Public Offering PaymentOfDeferredCostsOfInitialPublicOffering		usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution		usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	MDBH	Distribution Of Equity To Members And Subsequent Contribution DistributionOfEquityToMembersAndSubsequentContribution		usd
	MDBH	Ownership Change Of Noncontrolling Interest OwnershipChangeOfNoncontrollingInterest		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
	MDBH	Warrants Received As Part Of Investment Banking Deal WarrantsReceivedAsPartOfInvestmentBankingDeal		usd
	MDBH	Modification Of Lease Rightofuse Asset And Lease Liability ModificationOfLeaseRightofuseAssetAndLeaseLiability		usd
	MDBH	Record Rightofuse Asset And Operating Lease Liability RecordRightofuseAssetAndOperatingLeaseLiability		usd
	MDBH	Relienquishment Of Deferred Costs Of Initial Public Offering From Prior Year RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear		usd
	MDBH	Investment Securities At Cost Less Impairment Received In Lieu Of Cash Payment InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment		usd
	MDBH	Issuance Of Class Common Shares In Exchange For Noncontrolling Interest In Patentvest IssuanceOfClassCommonSharesInExchangeForNoncontrollingInterestInPatentvest		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	MDBH	Issuance Of Warrants To Purchase Class Stock Related To Private Placement Offering IssuanceOfWarrantsToPurchaseClassStockRelatedToPrivatePlacementOffering		usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain		usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain		usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
	MDBH	Contract With Customer Liability Amount Billed Not Recognized ContractWithCustomerLiabilityAmountBilledNotRecognized		usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2022Q3	MDBH	Contract With Customer Liability Amount Billed Not Recognized ContractWithCustomerLiabilityAmountBilledNotRecognized		usd
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2022Q4	MDBH	Contract With Customer Liability Amount Billed Not Recognized ContractWithCustomerLiabilityAmountBilledNotRecognized		usd
CY2022Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
	MDBH	Contract With Customer Liability Amount Billed Not Recognized ContractWithCustomerLiabilityAmountBilledNotRecognized		usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2023Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
	MDBH	Grants For Equipment Purchased GrantsForEquipmentPurchased		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	MDBH	Ownership Change Of Noncontrolling Interest OwnershipChangeOfNoncontrollingInterest		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Ratio Of Indebtedness To Net Capital1 RatioOfIndebtednessToNetCapital1	0.0667	pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41751
	dei	Entity Registrant Name EntityRegistrantName	MDB CAPITAL HOLDINGS, LLC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-4366624
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14135 Midway Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite G-150
	dei	Entity Address City Or Town EntityAddressCityOrTown	Addison
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75001
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75001
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	526-5000
	dei	Security12b Title Security12bTitle	Class A Common Shares, representing Limited Liability Interests
	dei	Trading Symbol TradingSymbol	MDBH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4295632	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24445550	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4952624	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	2000000	usd
CY2023Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	503777	usd
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	783520	usd
CY2023Q3	us-gaap	Grants Receivable GrantsReceivable	676452	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	809532	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	561536	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	309818	usd
CY2023Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7495988	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	16188920	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	4964725	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	832577	usd
CY2023Q3	MDBH	Investment Securities At Cost Less Impairment Broker Dealer InvestmentSecuritiesAtCostLessImpairmentBrokerDealer	50000	usd
CY2022Q4	MDBH	Investment Securities At Cost Less Impairment Broker Dealer InvestmentSecuritiesAtCostLessImpairmentBrokerDealer	50000	usd
CY2023Q3	MDBH	Investment Securities At Cost Less Impairment Non Broker Dealer InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer	300000	usd
CY2022Q4	MDBH	Investment Securities At Cost Less Impairment Non Broker Dealer InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer	200000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	323224	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	842306	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624644	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2126213	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1409732	usd
CY2023Q3	us-gaap	Assets Assets	43462770	usd
CY2022Q4	us-gaap	Assets Assets	25701071	usd
CY2023Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1040131	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	698782	usd
CY2023Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	154264	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	254745	usd
CY2023Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	158269	usd
CY2023Q3	MDBH	Deferred Ggrant Reimbursement DeferredGgrantReimbursement	153663	usd
CY2022Q4	MDBH	Deferred Ggrant Reimbursement DeferredGgrantReimbursement	214998	usd
CY2023Q3	MDBH	Deferred Tax Liabilities Net Current DeferredTaxLiabilitiesNetCurrent	225874	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2210005	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1423538	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4142206	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2592063	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45274523	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27764453	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6255406	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5124110	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	39019117	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22640343	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	301447	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	468665	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39320564	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23109008	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43462770	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25701071	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-786906	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16072	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	696965	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3836	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7	usd
	us-gaap	Fee Income FeeIncome	4233120	usd
CY2023Q3	us-gaap	Other Operating Income OtherOperatingIncome	11502	usd
CY2022Q3	us-gaap	Other Operating Income OtherOperatingIncome	57903	usd
	us-gaap	Other Operating Income OtherOperatingIncome	140873	usd
	us-gaap	Other Operating Income OtherOperatingIncome	107356	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-775404	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	73975	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	5070958	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	103513	usd
CY2023Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1337771	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1130256	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3183515	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2219954	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	273821	usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	514798	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	829474	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	882601	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	459585	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	51035	usd
	us-gaap	Professional Fees ProfessionalFees	1241089	usd
	us-gaap	Professional Fees ProfessionalFees	652713	usd
CY2023Q3	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	93326	usd
CY2022Q3	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	93465	usd
	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	408875	usd
	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	207944	usd
CY2023Q3	MDBH	Clearing And Other Charges ClearingAndOtherCharges	3316	usd
CY2022Q3	MDBH	Clearing And Other Charges ClearingAndOtherCharges	2547	usd
	MDBH	Clearing And Other Charges ClearingAndOtherCharges	382994	usd
	MDBH	Clearing And Other Charges ClearingAndOtherCharges	22342	usd
CY2023Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	327896	usd
CY2022Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	406536	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	883233	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1024761	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495715	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2198637	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6929180	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5010315	usd
CY2023Q3	MDBH	Research And Development Costs Net Of Grants Amounting ResearchAndDevelopmentCostsNetOfGrantsAmounting	743320	usd
CY2022Q3	MDBH	Research And Development Costs Net Of Grants Amounting ResearchAndDevelopmentCostsNetOfGrantsAmounting	645731	usd
	MDBH	Research And Development Costs Net Of Grants Amounting ResearchAndDevelopmentCostsNetOfGrantsAmounting	2265408	usd
	MDBH	Research And Development Costs Net Of Grants Amounting ResearchAndDevelopmentCostsNetOfGrantsAmounting	1651661	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27936	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103633	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67095	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	295779	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2523651	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2302270	usd
	us-gaap	Operating Expenses OperatingExpenses	6996275	usd
	us-gaap	Operating Expenses OperatingExpenses	5306094	usd
CY2023Q3	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-3299055	usd
CY2022Q3	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-2228295	usd
	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-1925317	usd
	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-5202581	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	176300	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	548479	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3122755	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2228295	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1376838	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5202581	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63559	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	384143	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3186314	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2228295	usd
	us-gaap	Profit Loss ProfitLoss	-1760981	usd
	us-gaap	Profit Loss ProfitLoss	-5202581	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-177853	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-144715	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-341631	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-418677	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3008461	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2083580	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1419350	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4783904	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23109008	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	54126	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1967941	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21195193	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	58951	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	3393274	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24647418	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17444659	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	65411	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	349390	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3186314	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	39320564	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6761337	usd
CY2022Q1	MDBH	Distribution Of Invizyne And Patent Vest To Members DistributionOfInvizyneAndPatentVestToMembers	-661799	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-209182	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5890356	usd
CY2022Q1	us-gaap	Temporary Equity Elimination As Partof Reorganization TemporaryEquityEliminationAsPartofReorganization	5890356	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6552155	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-2723700	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	325000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	54126	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1078704	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2678877	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	24746142	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	106940	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	56015	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1686400	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25901574	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25901574	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	54087	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2228295	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2228295	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23727366	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	23727366	usd
	us-gaap	Profit Loss ProfitLoss	-1760981	usd
	us-gaap	Profit Loss ProfitLoss	-5202581	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	696965	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3836	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	462467	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	164228	usd
	MDBH	Accretion Of Investments At Amortized Cost Us Treasury Bills AccretionOfInvestmentsAtAmortizedCostUSTreasuryBills	431776	usd
	MDBH	Payments To Acquire Investment Securities At Fair Value Made By Our Licensed Broker Dealer PaymentsToAcquireInvestmentSecuritiesAtFairValueMadeByOurLicensedBrokerDealer	1587500	usd
	MDBH	Payments For Proceeds Purchases Of Investment Securities At Cost Less Impairment PaymentsForProceedsPurchasesOfInvestmentSecuritiesAtCostLessImpairment	200000	usd
	MDBH	Proceeds From Sale Of Investment Securities At Fair Value ProceedsFromSaleOfInvestmentSecuritiesAtFairValue	632851	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	225874	usd
	MDBH	Proceeds From Warrants Issued As Part Of Investment Banking Deal ProceedsFromWarrantsIssuedAsPartOfInvestmentBankingDeal	165087	usd
	MDBH	Income Recognized From Warrants Received IncomeRecognizedFromWarrantsReceived	2645620	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	137972	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104614	usd
	MDBH	Accretion Of Deferred Grant Reimbursement AccretionOfDeferredGrantReimbursement	-38880	usd
	MDBH	Accretion Of Deferred Grant Reimbursement AccretionOfDeferredGrantReimbursement	-32909	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	69986	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	8626	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-133080	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	370516	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	251718	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	813	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	341348	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	38308	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	158269	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-100481	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	471814	usd
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-22455	usd
	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	80410	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5109442	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4934976	usd
	MDBH	Proceeds Of Investments Securities At Amortized Cost Us Treasury Bills ProceedsOfInvestmentsSecuritiesAtAmortizedCostUSTreasuryBills	15078020	usd
	MDBH	Payments To Acquire Investments Securities At Amortized Cost Us Treasury Bills PaymentsToAcquireInvestmentsSecuritiesAtAmortizedCostUSTreasuryBills	5953312	usd
	MDBH	Payments To Acquire Investments Securities At Amortized Cost Us Treasury Bills PaymentsToAcquireInvestmentsSecuritiesAtAmortizedCostUSTreasuryBills	11061058	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	355634	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	162416	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8769074	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11223474	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	25289660	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	19999992	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	436578	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2166698	usd
	MDBH	Payment Of Deferred Costs Of Initial Public Offering PaymentOfDeferredCostsOfInitialPublicOffering	480578	usd
	us-gaap	Payments Of Capital Distribution PaymentsOfCapitalDistribution	2723700	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	125000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17833294	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21523804	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	21492926	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5365354	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952624	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6225458	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26445550	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11590812	usd
	us-gaap	Interest Paid Net InterestPaidNet	9	usd
	MDBH	Distribution Of Equity To Members And Subsequent Contribution DistributionOfEquityToMembersAndSubsequentContribution	661799	usd
	MDBH	Ownership Change Of Noncontrolling Interest OwnershipChangeOfNoncontrollingInterest	436894	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6049225	usd
	MDBH	Warrants Received As Part Of Investment Banking Deal WarrantsReceivedAsPartOfInvestmentBankingDeal	2480533	usd
	MDBH	Modification Of Lease Rightofuse Asset And Lease Liability ModificationOfLeaseRightofuseAssetAndLeaseLiability	198544	usd
	MDBH	Record Rightofuse Asset And Operating Lease Liability RecordRightofuseAssetAndOperatingLeaseLiability	698249	usd
	MDBH	Relienquishment Of Deferred Costs Of Initial Public Offering From Prior Year RelienquishmentOfDeferredCostsOfInitialPublicOfferingFromPriorYear	323224	usd
	MDBH	Investment Securities At Cost Less Impairment Received In Lieu Of Cash Payment InvestmentSecuritiesAtCostLessImpairmentReceivedInLieuOfCashPayment	100000	usd
	MDBH	Issuance Of Class Common Shares In Exchange For Noncontrolling Interest In Patentvest IssuanceOfClassCommonSharesInExchangeForNoncontrollingInterestInPatentvest	200000	usd
	us-gaap	Stock Issued1 StockIssued1	65411	usd
	MDBH	Issuance Of Warrants To Purchase Class Stock Related To Private Placement Offering IssuanceOfWarrantsToPurchaseClassStockRelatedToPrivatePlacementOffering	106940	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24445550	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4952624	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	2000000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26445550	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4952624	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zEBtgCSzJovk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zZpsBnMexMQe">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period, as well as the disclosure of contingent assets and liabilities. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in the valuation of investment securities, valuing equity instruments issued for services, stock-based compensation and the realization of any deferred tax assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	MDBH	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	0	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	0	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	2000000	usd
CY2023Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7495988	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	16188920	usd
	MDBH	Net Of Grant Received NetOfGrantReceived	2332503	usd
	MDBH	Net Of Grant Received NetOfGrantReceived	1947440	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	172057	usd
	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-1925317	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	548479	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1376838	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	384143	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	4964725	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	832577	usd
CY2023Q3	MDBH	Investment Securities At Cost Less Impairment Broker Dealer InvestmentSecuritiesAtCostLessImpairmentBrokerDealer	50000	usd
CY2022Q4	MDBH	Investment Securities At Cost Less Impairment Broker Dealer InvestmentSecuritiesAtCostLessImpairmentBrokerDealer	50000	usd
CY2023Q3	MDBH	Investment Securities At Cost Less Impairment Non Broker Dealer InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer	300000	usd
CY2022Q4	MDBH	Investment Securities At Cost Less Impairment Non Broker Dealer InvestmentSecuritiesAtCostLessImpairmentNonBrokerDealer	200000	usd
CY2023Q3	MDBH	Unrealized Loss On Investments UnrealizedLossOnInvestments	786906	usd
CY2022Q3	MDBH	Unrealized Loss On Investments UnrealizedLossOnInvestments	16072	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	696965	usd
	MDBH	Unrealized Loss On Investments UnrealizedLossOnInvestments	3836	usd
CY2023Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7495988	usd
CY2023Q3	MDBH	Held To Maturity Securities Accumulated Unrecognized Holding Gains HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGains	693	usd
CY2023Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	7496681	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	16188920	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	51645	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	16137275	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	4964725	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	832577	usd
CY2023Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	2000000	usd
	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2024-07-26
	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.0225	pure
CY2023Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0775	pure
CY2023Q3	MDBH	Line Of Credit Facility Unused Capacity Fee LineOfCreditFacilityUnusedCapacityFee	5000	usd
CY2023Q3	us-gaap	Deposits Deposits	2002446	usd
CY2023Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1244659	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	889025	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	402353	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	264381	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	842306	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624644	usd
CY2023Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	43196	usd
CY2022Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	80680	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	107925	usd
CY2023Q3	MDBH	Contract With Customer Liability Amount Billed Not Recognized ContractWithCustomerLiabilityAmountBilledNotRecognized	200000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	809532	usd
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	468353	usd
	MDBH	Grant Costs Expensed GrantCostsExpensed	2180581	usd
	MDBH	Grant Costs Expensed GrantCostsExpensed	1596936	usd
	MDBH	Grants For Equipment Purchased GrantsForEquipmentPurchased	49626	usd
	MDBH	Grant Fees GrantFees	84827	usd
	MDBH	Grant Fees GrantFees	54725	usd
	MDBH	Grant Funds Received GrantFundsReceived	-2398488	usd
	MDBH	Grant Funds Received GrantFundsReceived	-1330771	usd
CY2023Q3	us-gaap	Grants Receivable GrantsReceivable	676452	usd
CY2022Q3	us-gaap	Grants Receivable GrantsReceivable	838869	usd
	MDBH	Grant Costs Expensed GrantCostsExpensed	2180581	usd
	MDBH	Grant Costs Expensed GrantCostsExpensed	1596936	usd
	MDBH	Total Grant Cost Expensed TotalGrantCostExpensed	2265408	usd
	MDBH	Total Grant Cost Expensed TotalGrantCostExpensed	1701287	usd
CY2023Q3	MDBH	Net Of Grant Received NetOfGrantReceived	771256	usd
CY2022Q3	MDBH	Net Of Grant Received NetOfGrantReceived	749364	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTPDf6zfq73h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z3TDrx29VG52">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to the Company’s current period presentation. In the previous fiscal year, we reclassified $<span id="xdx_901_eus-gaap--CompensationExpenseExcludingCostOfGoodAndServiceSold_c20230101__20230930_z3AGGowUfAFh" title="Compensation expense">11,040</span> of compensation expense to clearing and other charges.</span></p>
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	11040	usd
CY2023Q3	us-gaap	Noncurrent Assets NoncurrentAssets	2968519	usd
CY2023Q3	us-gaap	Assets Assets	43462770	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-786906	usd
CY2023Q3	us-gaap	Other Operating Income OtherOperatingIncome	11502	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-775404	usd
CY2023Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1337771	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	273821	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	459585	usd
CY2023Q3	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	93326	usd
CY2023Q3	MDBH	Clearing And Other Charges ClearingAndOtherCharges	3316	usd
CY2023Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	327896	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495715	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27936	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2523651	usd
CY2023Q3	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-3299055	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	176300	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3122755	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	63559	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3186314	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-177853	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3008461	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	696965	usd
	us-gaap	Fee Income FeeIncome	4233120	usd
	us-gaap	Other Operating Income OtherOperatingIncome	140873	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	5070958	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	3183515	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	829474	usd
	us-gaap	Professional Fees ProfessionalFees	1241089	usd
	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	408875	usd
	MDBH	Clearing And Other Charges ClearingAndOtherCharges	382994	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	883233	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6929180	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	67095	usd
	us-gaap	Operating Expenses OperatingExpenses	6996275	usd
	us-gaap	Profit Loss ProfitLoss	-1760981	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-341631	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1419350	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	2034376	usd
CY2022Q4	us-gaap	Assets Assets	25701071	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16072	usd
CY2022Q3	us-gaap	Other Operating Income OtherOperatingIncome	57903	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	73975	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1130256	usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	514798	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	51035	usd
CY2022Q3	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	93465	usd
CY2022Q3	MDBH	Clearing And Other Charges ClearingAndOtherCharges	2547	usd
CY2022Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	406536	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2198637	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103633	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2302270	usd
CY2022Q3	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-2228295	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2228295	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-2228295	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-144715	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2083580	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-3836	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7	usd
	us-gaap	Other Operating Income OtherOperatingIncome	107356	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	103513	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2219954	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	882601	usd
	us-gaap	Professional Fees ProfessionalFees	652713	usd
	us-gaap	Communications And Information Technology CommunicationsAndInformationTechnology	207944	usd
	MDBH	Clearing And Other Charges ClearingAndOtherCharges	22342	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1024761	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5010315	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	295779	usd
	us-gaap	Operating Expenses OperatingExpenses	5306094	usd
	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-5202581	usd
	MDBH	Net Operating Income Loss NetOperatingIncomeLoss	-5202581	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5202581	usd
	us-gaap	Profit Loss ProfitLoss	-5202581	usd
	us-gaap	Profit Loss ProfitLoss	-5202581	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-418677	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4783904	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4783904	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	MDBH	Weighted Average Non Controlling Percentage WeightedAverageNonControllingPercentage	0.426	pure
	MDBH	Weighted Average Non Controlling Percentage WeightedAverageNonControllingPercentage	0.3906	pure
	MDBH	Weighted Average Non Controlling Percentage WeightedAverageNonControllingPercentage	0.426	pure
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-341631	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	468665	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	522169	usd
	MDBH	Share Based Compensation To Non Controlling Interest ShareBasedCompensationToNonControllingInterest	174413	usd
	MDBH	Share Based Compensation To Non Controlling Interest ShareBasedCompensationToNonControllingInterest	164228	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	301447	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	704614	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	513750	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.53
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y29D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	513750	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.53
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	513750	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.44
	MDBH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P6Y10M2D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	563750	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.61
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M14D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	171249	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M2D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	278165	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y4M13D
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	829474	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	882601	usd
CY2022Q3	us-gaap	Area Of Land AreaOfLand	1300
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	1600	usd
CY2022Q1	us-gaap	Cash Available For Distributions CashAvailableForDistributions	2723700	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	697246	usd
CY2022	MDBH	Proceeds From Sale Of Investment Securities At Fair Value Made By Our Licensed Broker Dealer ProceedsFromSaleOfInvestmentSecuritiesAtFairValueMadeByOurLicensedBrokerDealer	632851	usd
CY2022	MDBH	Change In Fair Value ChangeInFairValue	64395	usd
CY2023Q3	MDBH	Venture Capital Net VentureCapitalNet	5787743	usd
CY2022Q3	MDBH	Venture Capital Net VentureCapitalNet	2521585	usd
CY2023Q3	srt	Minimum Net Capital Required1 MinimumNetCapitalRequired1	1195542	usd
CY2023Q3	srt	Net Capital NetCapital	79703	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	391960	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	197528	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	usd
CY2023Q3	MDBH	License Fees LicenseFees	1250	usd
CY2022Q3	MDBH	License Fees LicenseFees	625	usd
	MDBH	License Fees LicenseFees	3750	usd
	MDBH	License Fees LicenseFees	1875	usd
CY2023Q2	us-gaap	Advance Rent AdvanceRent	13277	usd
CY2023Q2	MDBH	Base Rent BaseRent	14943	usd
CY2023Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P21M
CY2021Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2021Q3	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend for 60 additional months
CY2023Q2	us-gaap	Advance Rent AdvanceRent	14371	usd
CY2023Q2	MDBH	Base Rent BaseRent	16259	usd
CY2023Q2	MDBH	Annual Operating Cost Increase Percentage AnnualOperatingCostIncreasePercentage	0.025	pure
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P91M
CY2022Q3	us-gaap	Advance Rent AdvanceRent	12556	usd
CY2022Q3	MDBH	Base Rent BaseRent	13937	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2126213	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1409732	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2210005	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1423538	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y5M8D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M13D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0766	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0671	pure
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	206837	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	147661	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	896803	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	813003	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	276823	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	106980	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29049	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19200	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	305872	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	126180	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	121688	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	491624	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	503684	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	516001	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	528586	usd
CY2023Q3	MDBH	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	576564	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2738147	usd
CY2023Q3	MDBH	Less Effects Of Discounting LessEffectsOfDiscounting	-528142	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2210005	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure

Files In Submission

Name	View Source	Status
0001493152-23-041312-index-headers.html	Edgar Link	pending
0001493152-23-041312-index.html	Edgar Link	pending
0001493152-23-041312.txt	Edgar Link	pending
0001493152-23-041312-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
mdbh-20230930.xsd	Edgar Link	pending
mdbh-20230930_cal.xml	Edgar Link	unprocessable
mdbh-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mdbh-20230930_lab.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
mdbh-20230930_pre.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MDBH
MDB Capital Holdings LLC Stock $mdbh

2023 Q4 Form 10-Q Financial Statement

#000149315223041312 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDBH MDB Capital Holdings LLC Stock $mdbh

2023 Q4 Form 10-Q Financial Statement

#000149315223041312 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MDBH
MDB Capital Holdings LLC Stock $mdbh